Non Melanoma Skin Cancer Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Non Melanoma Skin Cancer Market is Segmented By Treatment (Immunotherapy, Radiation Therapy, Chemotherapy, Photodynamic Therapy, Others), By Indication (Basal cell carcinoma, Squamous cell carcinoma, T Cell Lymphoma), By End-User (Hospitals, Ambulatory surgical centers, Speciality Clinics, Others), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Non Melanoma Skin Cancer Market Size

The Global Non Melanoma Skin Cancer Market reached USD 645.7 million in 2022 and is projected to witness lucrative growth by reaching up to USD 911.9 million by 2031. The non melanoma skin cancer market is expected to exhibit a CAGR of 4.5% during the forecast period (2024-2031).  Non-melanoma skin cancers typically develop in the skin's outermost layer (epidermis) and are frequently termed after the particular type of skin cell from which they arise. Basal cell carcinoma (BCC), sometimes known as a rodent ulcer, begins in the cells lining the bottom of the epidermis and accounts for around 75 out of every 100 skin malignancies. 

Squamous cell carcinoma (SCC) begins in the cells that line the top of the epidermis and accounts for around 20 percent of all skin malignancies.

Furthermore, non melanoma skin cancer market size is growing rapidly because of a following factors innovation of new products, increasing numbers of clinical trails, rising product demand and surging health care expenditure etc.

Non Melanoma Skin Cancer Market Scope

To Know More Insights - Download Sample

Non Melanoma Skin Cancer Market Dynamics

Increasing Prevalence of Non Melanoma Skin Cancer 

One of the major drivers assisting the market's growth over the forecast  period is the increasing  prevalence of non melanoma skin cancer. For instance, according to WHO, there are around 2 to 3 million non-melanoma skin cancer cases worldwide each year. 

Every year, Australia has the largest number of malignant melanoma instances. This is 10 to 20 times more than the population of Europe. Melanoma of the skin is the 17th most frequent malignancy worldwide. It is the 13th most prevalent cancer in males and the 15th most common cancer in women. In 2020, New Zealand had the greatest rate of melanoma cancer-related fatalities, followed by Norway.

Rising Geriatric Population Across the Globe

Age is a substantial risk factor for all types of skin cancer. Non-melanoma skin cancer (NMSC; also known as squamous cell carcinoma [SCC] and basal cell carcinoma [BCC]) is the most prevalent kind of cancer identified worldwide, and it disproportionately affects older people. Because of their extended lifetime of sun exposure, older people are at a higher risk of getting non-melanoma skin cancer. Fair skin, a history of sunburns, a compromised immune system, exposure to particular chemicals or radiation, and a family history of skin cancer are all risk factors.

For instance, according to the Skin Cancer Foundation 1 in 5 Americans will develop skin cancer by the age of 70. More than 2 people die of skin cancer in the U.S. every hour. Having 5 or more sunburns doubles your risk for melanoma. When detected early, the 5-year survival rate for melanoma is 99%. 

High Cost of Treatment 

High cost of non melanoma skin cancer treatment is one of the restraint that hinders the market. Cancer therapy costs more than four times as much as treatment for other prevalent health diseases, with an average cost of $150,000. According to the Centres for Disease Control and Prevention (CDC), treatment for all types of skin cancer costs at least $8 billion each year. 

Non Melanoma Skin Cancer Market Segment Analysis

The global non melanoma skin cancer  is segmented based on treatment type, indication type , end user and region.

The Immunotherapy Treatment  Segment Accounted For Approximately 22.9% of The Non Melanoma Skin Cancer Share

Immunotherapy treatment segment with around 22.9% is expected during the forecast period. Immunotherapy is a form of cancer treatment in which the body's immune system aids in the fight against cancer. The immune system assists the body in fighting infections and other disorders. It is made up of white blood cells as well as lymphatic organs and tissues. Immunotherapy falls within the category of biological treatment and can be used to treat a wide range of cancers. 

For instance, in November 2022, LIBTAYO (cemiplimab), the first immunotherapy approved in Australia for the treatment of advanced cutaneous squamous cell carcinoma (CSCC), will be accessible under the Pharmaceutical Benefits Scheme (PBS). LIBTAYO will be approved by the PBS for people with metastatic or locally advanced cutaneous squamous cell carcinoma when curative surgery and radiation are ineffective.

Source: DataM Intelligence Analysis (2023)

Global Non Melanoma Skin Cancer Market Geographical Share

North America Accounted for Approximately 40.8% of the Market Share in 2022.

North America is estimated to hold about 40.8% of the total market share throughout the forecast period. The United States government has also developed favorable reimbursement policies for the treatment of melanoma diseases that are an attempt to fulfill unmet patient needs. Furthermore, the presence of numerous new players is expected to drive the overall market.

For instance, according to American Academy of Dermatology Association they have been huge rise of skin cancer in United States. Based on  current projections, one in every five Americans will acquire skin cancer in their lifetime. Every day, an estimated 9,500 people in the United States are diagnosed with skin cancer. According to research, Non Melanoma Skin Cancer (NMSC), Which Includes Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), affects more than 3 million Americans each year. Between 1976-1984 and 2000-2010, the total incidence of BCC grew by 145%, whereas the overall incidence of SCC increased by 263%.

Source: DataM Intelligence Analysis (2023)

Non Melanoma Skin Cancer Market Companies 

The major global players in the non melanoma skin cancer market include Merck and Co Inc, Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann La Roche AG and Novartis AG, Amgen others.

COVID-19 Impact on Non Melanoma Skin Cancer Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global non melanoma skin cancer market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global non melanoma skin cancer  growth over the forecast period.

By Treatment type 

• Immunotherapy
• Radiation Therapy
• Chemotherapy
• Photodynamic Therapy
• Others

By Indication type

• Basal cell carcinoma
• Squamous cell carcinoma
• T Cell Lymphoma 

By End user

• Hospitals
• Ambulatory surgical centers
• Speciality Clinics 
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• In May 2023, FDA granted regular approval to cemiplimab for metastatic basal cell carcinoma. FDA has granted cemiplimab-rwlc (libtayo) full clearance for the treatment of patients with metastatic basal cell carcinoma who have previously received a hedgehog inhibitor (HHI). This study included 138 patients with locally advanced or metastatic, nodal or distant basal cell carcinoma who had progressed on an hhi, had not reacted after 9 months of hhi therapy, or had proven to be intolerant to previous hhi treatment.
• In May 2023, Almirall and CRG announced non-melanoma skin cancer research collaboration with Almirall SA and biomedical research institute, the Centre for Genomic Regulation, a collaboration aimed at developing and distinguishing novel preclinical models to identify new treatments for non-melanoma skin cancer (NMSC).
• In January 2023, FDA approval sought for cosibelimab in advanced cutaneous squamous cell carcinoma cosibelimab (formerly CK-301), an investigational anti-PD-L1 antibody, has been submitted to the FDA for the treatment of patients with metastatic cutaneous squamous cell carcinoma or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or radiation.

Why Purchase the Report?

• To visualize the global non melanoma skin cancer market segmentation based on treatment, indication, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of non melanoma skin cancer market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global non melanoma skin cancer market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies